

HOLLIS, MARK Registration Number: 456789

# Snapshot

Prescribing Quarter 3, 2018



### Three Month Prescribing Snapshot: Opioids (1), including codeine

	Your Practice	Comparator Group Median (2)	Your Percentile
Patient(s) receiving opioids prescribed by you	19	21	47.9
Total OME/day (3)	967	272.8	74.1
OME/day/patient (4)	51	13.1	90.7
Patient(s) receiving opioids at an average dose of 90 OME/day or higher (5)	3		
Patient(s) receiving one or more opioid(s) and one or more BDZ/Z prescribed by you (6)	4	_	
Patient(s) receiving three or more different opioids (5)	0	-	
Opioid naive patient(s) receiving a long-acting opioid prescribed by you (7)	0	_	
Patient(s) receiving opioids from three or more prescribers	0	_	

- (1) The opioid analytic group includes drug dispenses for opiates, opioids and certain non-opioid drugs (butalbital and ketamine). Non-opioid drugs and opioid drugs assigned an oral morphine equivalent (OME) value of zero (methadone and buprenorphine) do not contribute to total opioid dose calculations. These contribute to ingredient counts only. Codeine is included in all measures.
- (2) Comparator groups are clusters of specialty groups with similar clinical practices and distribution within an analytical drug class. You are being compared to your peers who belong to the same group as you. Practice setting information from your annual renewal was used to determine your assignment to a group.
- (3) Total OME/day prescribed is calculated by dividing the total oral morphine equivalents (OME) dispensed to patients from your prescriptions, divided by the number of days in the quarter.
- (4) OME/day/patient average is calculated by dividing the Total OME/day you prescribed by the number of patients to whom you prescribed an opioid.
- (5) Prescribers other than you, including pharmacists, nurse practitioners and dentists, who may have prescribed an opioid to your patient contribute towards this measure.
- (6) BDZ/Z category includes dispenses for benzodiazepine and benzodiazepine-like drugs or Z-drugs (i.e. Zopiclone, Zaleplon or Zolpidem).
- (7) Opioid naive patients are those with no opioid dispenses in the previous 180 days. Long-acting opioids include agents that have a long serum half-life or a controlled or extended-release delivery mechanism.

## Patient(s) receiving opioids at an average dose of 90 OME/day or higher

Name	PHN	SEX	DOB	OME/day
Brenner, Simon	UL000000000	М	1972-10-11	635.6
Harris, Lee	UL000000000	F	1969-10-12	116.3
Webb, Paul	UL000000000	М	1960-09-03	102.9

### Patient(s) receiving one or more opioid(s) and one or more BDZ/Z prescribed by you

Name	PHN	SEX	DOB
Marsh, Mitch	UL000000000	М	1984-10-10
Gibbons, Beverley	UL000000000	F	1978-05-21
Webb, Paul	UL000000000	М	1960-09-03





Doyle, Markus UL000000000 M 1980-05-27

End of Opioid data





# Three Month Prescribing Snapshot: Benzodiazepines and Z-drugs (BDZ/Z) (8)

	Your Practice	Comparator Group Median (9)	Your Percentile
Patient(s) receiving a BDZ/Z prescribed by you	24	27	46.9
Total DDDs (10)	7.1	12.4	38.5
DDDs/patient (11)	0.3	0.5	24.3
Patient(s) receiving BDZ/Z at an average dose of 2 DDDs or higher (12)	0		
Patient(s) receiving three or more different BDZ/Z (12)	0		
Patient(s) receiving BDZ/Z from three or more prescribers	3	_	
Senior(s) to whom you prescribed BDZ/Z (13)	1	<del>-</del>	

<sup>(8)</sup> BDZ/Z category includes dispenses for benzodiazepine and benzodiazepine-like drugs or Z-drugs (i.e. Zopiclone, Zaleplon or Zolpidem).

<sup>(13)</sup> Patients 65 years of age and over who received a BDZ/Z drug prescribed by you.

Patient(s) receiving BDZ/Z from three or more prescribers					
Name	PHN	SEX	DOB	Prescribers	
Girl, Dee Dee	UL000000000	F	1969-12-13	4	
McIntosh, Robbie	UL000000000	М	1976-03-17	4	
Rhodes, David	UL000000000	М	1954-10-13	3	
Senior(s) to whom you prescribed BDZ/Z					
Name	PHN	SEX	DOB	DDDs	
Garbarek, Anja	UL000000000	F	1948-12-03	0.0	

This report was generated using data from Netcare PIN, current as of September 30, 2018



<sup>(9)</sup> Comparator groups are clusters of specialty groups with similar clinical practices and distribution within an analytic drug class. You are being compared to your peers who belong to the same group as you. Practice setting information from your annual renewal was used to determine your assignment to a group.

<sup>(10)</sup> BDZ/Z doses are measured in multiples of Defined Daily Doses (DDDs). The Defined Daily dose of a drug is the average daily maintenance dose for its main indication in adults. Total DDDs prescribed is calculated by dividing the total DDDs patients received from your prescriptions by the number of days in the quarter.

<sup>(11)</sup> DDDs/patient is calculated by dividing the Total DDDs by the number of patients dispensed BDZ/Z prescribed by you within the quarter.

<sup>(12)</sup> Prescribers other than you, including pharmacists, nurse practitioners and dentists, who may have prescribed an BDZ/Z to your patient contribute towards this measure.